Tagged with DGE

China There are over 7,000 different rare diseases globally, many of which affect only a handful of patients. However, given the scale of China’s population, rare diseases in the country take on an increased significance, something that Chinese policymakers have worked to address in recent years.   “China now introduces new…

China Dr James Xue, founder, chairman and CEO of CANbridge Pharmaceuticals shares the career journey that led him to China’s first rare disease-focused company and the role CANbridge is playing in shaping policies relating to rare diseases, such as the National Rare Disease List. Xue also outlines the company’s robust pipeline…

Middle East & Africa As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover that the volatility of these geographies often meant that the expected returns did not materialise. However, especially post-COVID, emerging markets…

UAE NewBridge Pharmaceuticals’ Joe Henein describes how his MENA-focused specialty innovative biopharma distributor has developed over the last 13 years to become a market leader; looks at some of the key trends shaping the market in his region; and reinforces his commitment to bridging the gap and delivering therapies to patients…

China Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic alternatives, China and its sizeable biopharma industry now face a challenging path…

China Vaccinating the elderly has been a key factor in ensuring protection against fatality during COVID-19, writes Bridge Consulting’s Stefania Jiang. However, the experience of it in China has been one of ups and downs as vaccine hesitancy and a slew of social issues have greatly affected uptake. But ultimately, this…

Global PharmaBoardroom’s network of thought leaders continued to provide some of our top content in 2022, covering topics such as Africa’s first integrated drug discovery platform,  Chinese vaccine exports, inequities in US healthcare, antimicrobial pollution and new pharmaceutical legislation in Europe. See our dedicated op-ed page for all of the year’s contributions…

Taiwan Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have to play in more effective COVID-19 diagnostics.   Given our status as a raw materials developer, we see an opportunity…

UAE NewBridge Pharmaceuticals, a specialty pharma company with Dubai as its regional headquarters for the MENA region, is celebrating its 10th anniversary in 2020. President and CEO Joe Henein discusses the company’s journey to becoming the partner of choice for US and European companies looking to bring their innovative products to…

Korea James Jungkue Lee, founder and CEO of Bridge Biotherapeutics, explains his strategy for risk mitigation in running a virtual biotech start-up. He also offers his insights into the company’s partnership strategy and shares his opinion on why Korea will become a global leader in biotech.   Biotech is a very…

France Thomas Courbe, general director of the DGE (Direction Générale des Entreprises – General Directorate for Enterprises), speaks about the role of the DGE and the implementation of new policies oriented towards France’s new pro-business direction, specifically in the life sciences industry.   France is becoming the pro-business model in Europe.…

Pharma Puerto Rico is starting to move towards greater R&D activity. World class research centers in cardiovascular, oncology, and soon molecular science are putting the territory on the global map for pharmaceutical research. But Puerto Rico is starting to move beyond manufacturing and towards greater R&D activity. Puerto Rico’s Cardiovascular and…